MPP Unveils Quartet Of Nilotinib Licensees

Four firms – India’s Eugia, Hetero and Dr Reddy's, along with Indonesian-based company BrightGene – have been selected by the Medicines Patent Pool to manufacture generic versions of Novartis’s nilotinib treatment for chronic myeloid leukemia as sub-licensees, as part of an MPP licensing deal with the originator.

The quartet of firms will be able to manufacture generic versions of nilotinib in India and seven middle-income countries where patents on the product are pending or in force – Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia – and supply it in 44 territories included